N-Acetyl Selank Amidate is a synthetically modified analogue of the regulatory peptide Selank, a tuftsin-derived glyproline originally characterized in preclinical neurobiological research. Structural modifications at both the N- and C-termini are employed to alter physicochemical stability and resistance to enzymatic degradation. In experimental settings, Selank and its derivatives have been utilized as molecular probes to investigate transcriptional regulation, receptor-associated signaling pathways, and peptide transport mechanisms in cellular and in-vivo animal models.

Sequence: Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro
Molecular Formula: C₃₅H₅₉N₁₁O₁₀
Molecular Weight: 793.92 g/mol
CAS Number: 2212313-10-6
Synonyms: Selanc, TP-7

N-terminal acetylation and C-terminal amidation are common peptide modifications known to influence charge distribution, steric configuration, and proteolytic stability. These structural features are routinely examined in peptide chemistry to assess alterations in molecular persistence and receptor interaction under controlled laboratory conditions.

In laboratory research environments, N-Acetyl Selank Amidate has been applied as a tool compound for:

• Evaluation of peptide-mediated transcriptional modulation in neuronal and immune-related cell cultures
• Investigation of glyproline transport dynamics across cellular barrier models
• Assessment of cytokine-associated signaling pathways in rodent systems
• Comparative analysis of peptide stability and receptor affinity following terminal modification

Preclinical investigations indicate that Selank-derived peptides are capable of modulating gene expression networks associated with neurotransmitter signaling, cytokine regulation, and synaptic plasticity. Transcriptomic analyses in rodent models have identified differential regulation of multiple gene clusters linked to GABAergic signaling, membrane ion transport, and neurotrophin-associated pathways.

As a member of the glyproline peptide family, Selank exhibits physicochemical properties that facilitate interaction with peptide transport systems. These properties have been examined in relation to peptide distribution within central nervous system tissues under experimental conditions.

Across published preclinical literature, Selank and structurally modified analogues have been reported to influence transcriptional accessibility, cytokine expression profiles, and receptor-associated signaling cascades in cellular and animal models. Observed effects are interpreted within experimental frameworks focused on molecular regulation rather than physiological outcomes. These findings support continued use of Selank-based peptides as mechanistic probes in neurogenetic and immunoregulatory research.

This material is supplied as a laboratory research reagent. Analytical characterization may include mass spectrometry, chromatographic purity assessment, and structural verification techniques appropriate for synthetic peptides. Researchers should consult lot-specific documentation for analytical specifications relevant to experimental reproducibility.

The above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

The main research direction of Svetlana Limborska is molecular human genetics, including the study of the structural and functional organization of the genome, molecular genetic analysis of populations and the identification of the molecular basis of hereditary and socially important diseases including stroke. It was determined the molecular mechanisms of genomic alterations for a number of human diseases, including hemoglobinopathies, thalassemia, myodystrophy, torsion dystonia, Parkinson’s disease, Wilson’s disease and others; it was discovered a family of hypervariable DNAs, which were universally distributed in the genomes of all living organisms and were found to be suitable for both the personal identification and kinship purposes; some new brain-specific human genes were found and characterized, and it was identified wide-scale changes in the transcriptome of nerve cells after ischemia and under the action of peptide drugs.

Dr. Svetlana Limborska is being referenced as one of the leading scientists involved in the research and development of Cardiogen. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Dr. Svetlana Limborska is listed in [1] and [9] under the referenced citations.

1. A. Volkova et al. “Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission,” Front. Pharmacol., vol. 7, p. 31, Feb. 2016, doi: 10.3389/fphar.2016.00031.
2. A. Kasian et al. “Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission,” Front. Pharmacol., vol. 7, p. 31, Feb. 2016, doi: 10.3389/fphar.2016.00031.
3. Z. V. Bakaeva et al., “Glyprolines exert protective and repair-promoting effects in the rat stomach: potential role of the cytokine GRO/CINC-1,” J. Physiol. Pharmacol. Off. J. Pol. Physiol. Soc. vol. 2017, p. 5091027, 2017, doi: 10.1155/2017/5091027.
4. “Immunomodulatory effects of selank in patients with anxiety-asthenic disorders” O. N. Uchakina et al., “[Immunomodulatory effects of selank in patients with anxiety-asthenic disorders],” Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova, vol. 108, no. 5, pp. 71–75, 2008.
5. A. A. Zozulia et al., “Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia,” Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova, vol. 108, no. 4, pp. 38–48, 2008.
6. L. A. Liapina, V. E. Pastorova, T. I. Obergan, G. E. Samonina, I. P. Ashmarin, and N. F. Miasoedov, “Comparison of anticoagulant effects of regulatory proline-containing oligopeptides. Specificity of glyprolines, semax, and selank and potential of their practical application,” Izv. Akad. Nauk. Ser. Biol., no. 2, pp. 193–203, Apr. 2006.
7. L. A. Liapina, V. E. Pastorova, T. I. Obergan, G. E. Samonina, I. P. Ashmarin, and N. F. Miasoedov, “Comparison of anticoagulant effects of regulatory proline-containing oligopeptides. Specificity of glyprolines, semax, and selank and potential of their practical application,”
8. G. N. Kopylova, E. A. Smirnova, L. T. Sanzhieva, B. A. Umarova, T. V. Lelekova, and G. E. Samonina, “Glyprolines and semax prevent stress-induced microcirculatory disturbances in the mesentery,” Bull. Exp. Biol. Med., vol. 136, no. 5, pp. 441–443, Nov. 2003, doi: 10.1023/b:bebm.0000017087.90585.a9.
9. T. A. Kolomin et al., “Transcriptome alteration in hippocampus under the treatment of tuftsin analog Selank,” Zh. Vyssh. Nerv. Deiat. Im. I. P. Pavlova, vol. 63, no. 3, pp. 365–374, Jun. 2013, doi: 10.7868/s0044467713030052.
10. E. Linster and M. Wirtz, “N-terminal acetylation: an essential protein modification emerges as an important regulator of stress responses,” J. Exp. Bot., vol. 69, no. 19, pp. 4555–4568, Aug. 2018, doi: 10.1093/jxb/ery241.
11. R. Ree, S. Varland, and T. Arnesen, “Spotlight on protein N-terminal acetylation,” Exp. Mol. Med., vol. 50, no. 7, pp. 1–13, Jul. 2018, doi: 10.1038/s12276-018-0116-z.
12. “Amidation – an overview | ScienceDirect Topics.” https://www.sciencedirect.com/topics/engineering/amidation.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.

For Laboratory Research Only. Not for human use, medical use, diagnostic use, or veterinary use.